June 28, 2017 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the “OTC”) markets, provides a corporate update. VANC is pleased to announce that it has closed on $661,298.85 Cdn in financing equating to 4,408,659 units of the Company at a price of $0.15 […]